HLUN-B - H Lundbeck A/S - Stock Price & Dividends

H. Lundbeck A/S is a biopharmaceutical company that focuses on developing and commercializing innovative treatments for psychiatric and neurological disorders. With a rich history dating back to 1915, the company has established itself as a leader in the industry, operating in Europe, the United States, and internationally.

The company's product portfolio is diverse and comprehensive, featuring a range of medications that address various mental health and neurological conditions. Some of its key products include Abilify Maintena/Abilify Maintena for schizophrenia and bipolar I disorder, Brintellix/Trintellix for depressive disorders, and Northera for symptomatic neurogenic orthostatic hypotension. Additionally, Lundbeck offers Vyepti for migraine prevention, Rexulti/Rxulti for major depressive disorder (MDD) and schizophrenia, and Azilect for Parkinson's disease.

Lundbeck's commitment to improving patient outcomes is also reflected in its other products, such as Cipralex/Lexapro for depression, Ebixa for dementia, Onfi for epilepsy, Sabril for refractory complex partial seizures and infantile spasms, Xenazine for chorea, Deanxit for depression, Cipramil for depression and anxiety, and Cisordinol for psychosis. The company's products are primarily sold to distributors of pharmaceuticals, pharmacies, and hospitals.

Lundbeck has formed strategic partnerships to drive innovation and growth. One notable partnership is with Otsuka Pharmaceuticals Co., Ltd., while another collaboration is with Alloy Therapeutics, Inc. for the discovery of novel biologics therapies. By leveraging these partnerships, Lundbeck is well-positioned to continue developing cutting-edge treatments that address significant unmet medical needs.

Headquartered in Valby, Denmark, Lundbeck is a forward-thinking company that is dedicated to making a positive impact on the lives of patients and their families. For more information, please visit the company's website at https://www.lundbeck.com.